Company Registry

Icogenex Corporation (AKA:Icogen Corporation)
Profile last edited on: 2/11/2020

Identification of protein effectors for development of therapeutic drugs
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

454 North 34th Street
Seattle, WA 98112
   (206) 545-2880
Multiple Locations:   
Congressional District:   07
County:   King

Public Profile

Previously called Icogen Corporation, Icogenex is using ICOCEPTTM, its platform technology, to identify therapeutically useful molecules for the treatment of inflammatory diseases, Alzheimer's disease, and diseases involving inappropriate proteolytic processing.proven capabilities in expressing proteins from bacteria, yeast and mammalian cells. With proven capabilities in expressing proteins from bacteria, yeast and mammalian cell., the company partners with pharmaceutical companies, provides contract research services and leverages in-house drug development projects to express therapeutic proteins.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Frederick S Hagen -- President

  Joseph Day --

  Theo Devos --

  Jerry McGuire -- CFO

  Richard A Swank --

  David Webster -- Director Business Development

SBIR firms in the news

There are no news available.